Howard A Liebman

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. ncbi request reprint Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia
    Howard A Liebman
    Internal Medicine, Jane Anne Nohl Division of Hematology, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA
    Haematologica 101:1327-1332. 2016
  2. doi request reprint Immune modulation for autoimmune disorders: evolution of therapeutics
    Howard A Liebman
    Department of Medicine and Pathology, Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA Electronic address
    Semin Hematol 53:S23-6. 2016
  3. doi request reprint Incidental venous thromboembolic events in cancer patients: what we know in 2016
    Howard A Liebman
    Jane Ann Nohl Division of Hematology and Center for the Study of Blood Diseases, University of California Keck School of Medicine, Los Angeles, CA, USA Electronic address
    Thromb Res 140:S18-20. 2016
  4. doi request reprint Thrombocytopenia in cancer patients
    Howard A Liebman
    Jane Ann Nohl Division of Hematology and Center for the Study of Blood Diseases, Keck School of Medicine of the University of Southern California, Los Angeles, CA Electronic address
    Thromb Res 133:S63-9. 2014
  5. pmc Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia
    Eric Cheung
    Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
    Biologics 3:57-62. 2009
  6. doi request reprint Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study
    Howard A Liebman
    Internal Medicine, Jane Anne Nohl Division of Hematology, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA
    Br J Haematol 162:693-701. 2013
  7. ncbi request reprint Heparin-induced thrombocytopenia: diagnosis and management
    Howard A Liebman
    University of Southern California Keck School of Medicine, Jane Anne Nohl Division of Hematology, Center for the Study of Blood Diseases, Los Angeles, CA, USA
    Vascular 16:S71-6. 2008
  8. doi request reprint Recognizing and treating secondary immune thrombocytopenic purpura associated with lymphoproliferative disorders
    Howard A Liebman
    Jane Anne Nohl Division of Hematology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Semin Hematol 46:S33-6. 2009
  9. doi request reprint Heparin-platelet factor 4 antibodies are frequent after vascular surgery but are not a frequent cause of graft thrombosis or thrombocytopenia
    Tamas Alexy
    Department of Physiology and Biophysics, Los Angeles County University of Southern California USC Medical Center, USC University Hospital, Los Angeles, California, USA
    J Vasc Surg 48:377-81. 2008
  10. doi request reprint Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation
    Ilene C Weitz
    Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles 90033, CA, USA
    Thromb Res 130:361-8. 2012

Collaborators

Detail Information

Publications30

  1. ncbi request reprint Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia
    Howard A Liebman
    Internal Medicine, Jane Anne Nohl Division of Hematology, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA
    Haematologica 101:1327-1332. 2016
    ..Platelet responses and bleeding reduction occurred in all dose groups, and response durability appeared to improve with higher doses. Clinicaltrials.gov identifier: NCT00547066...
  2. doi request reprint Immune modulation for autoimmune disorders: evolution of therapeutics
    Howard A Liebman
    Department of Medicine and Pathology, Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA Electronic address
    Semin Hematol 53:S23-6. 2016
    ....
  3. doi request reprint Incidental venous thromboembolic events in cancer patients: what we know in 2016
    Howard A Liebman
    Jane Ann Nohl Division of Hematology and Center for the Study of Blood Diseases, University of California Keck School of Medicine, Los Angeles, CA, USA Electronic address
    Thromb Res 140:S18-20. 2016
    ..Based upon these studies, current guidelines recommend treatment for incidental PE as recommended for symptomatic PE. ..
  4. doi request reprint Thrombocytopenia in cancer patients
    Howard A Liebman
    Jane Ann Nohl Division of Hematology and Center for the Study of Blood Diseases, Keck School of Medicine of the University of Southern California, Los Angeles, CA Electronic address
    Thromb Res 133:S63-9. 2014
    ..The goal of treatment should be to maintain a safe platelet count to allow effective treatment of the underlying malignancy, prevent bleeding complications and to minimize the use of platelet product transfusion...
  5. pmc Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia
    Eric Cheung
    Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
    Biologics 3:57-62. 2009
    ..Recommendations have been proposed to reduce the risk of these complications. Anti-D immunoglobulin can be an effective option for rapidly increasing platelet counts in patients with symptomatic ITP...
  6. doi request reprint Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study
    Howard A Liebman
    Internal Medicine, Jane Anne Nohl Division of Hematology, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA
    Br J Haematol 162:693-701. 2013
    ..Low-dose SC veltuzumab appears convenient, well-tolerated, and with promising clinical activity in relapsed ITP.(Clinicaltrials.gov identifier: NCT00547066.)...
  7. ncbi request reprint Heparin-induced thrombocytopenia: diagnosis and management
    Howard A Liebman
    University of Southern California Keck School of Medicine, Jane Anne Nohl Division of Hematology, Center for the Study of Blood Diseases, Los Angeles, CA, USA
    Vascular 16:S71-6. 2008
    ..Owing to the high risk of thrombosis associated with HIT, antithrombotic therapy with direct thrombin inhibitors (lepirudin or argatroban) should be started when serologic assays confirm clinical suspicion...
  8. doi request reprint Recognizing and treating secondary immune thrombocytopenic purpura associated with lymphoproliferative disorders
    Howard A Liebman
    Jane Anne Nohl Division of Hematology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Semin Hematol 46:S33-6. 2009
    ....
  9. doi request reprint Heparin-platelet factor 4 antibodies are frequent after vascular surgery but are not a frequent cause of graft thrombosis or thrombocytopenia
    Tamas Alexy
    Department of Physiology and Biophysics, Los Angeles County University of Southern California USC Medical Center, USC University Hospital, Los Angeles, California, USA
    J Vasc Surg 48:377-81. 2008
    ..A prospective study was conducted to monitor the development and function of platelet factor 4 (PF4)/heparin antibodies after infrainguinal bypass procedures and to evaluate their clinical significance in early graft occlusion...
  10. doi request reprint Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation
    Ilene C Weitz
    Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles 90033, CA, USA
    Thromb Res 130:361-8. 2012
    ....
  11. pmc Treating venous thromboembolism in patients with cancer
    Caroline Piatek
    Jane Anne Nohl Division of Hematology, Department Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Expert Rev Hematol 5:201-9. 2012
    ..Novel oral agents are currently being investigated and may play a role in the future in the treatment of cancer-associated VTE...
  12. ncbi request reprint Secondary immune thrombocytopenic purpura
    Howard A Liebman
    University of Southern California Keck School of Medicine, Los Angeles, California, USA
    Curr Opin Hematol 14:557-73. 2007
    ..The guidelines did not address thrombocytopenia resulting from autoimmune disorders or chronic infections such as Helicobacter pylori, hepatitis C virus or HIV...
  13. pmc Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism
    David A Manly
    Division of Hematology Oncology, Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7035, USA
    Thromb Res 125:511-2. 2010
    ..7+/-3.8 pg/mL vs 0.6+/-0.4 pg/mL, p<0.05). Further prospective studies are required to determine if levels of MP TF activity may be a useful biomarker to identify patients at increased risk for VTE...
  14. pmc Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy
    Jeffrey I Zwicker
    Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Clin Cancer Res 15:6830-40. 2009
    ..We evaluated the hypothesis that tumor-derived tissue factor-bearing microparticles in plasma contribute to cancer-associated thrombosis...
  15. ncbi request reprint The role of oral anticoagulants in tumor biology
    Ilene C Weitz
    Division of Hematology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    Semin Thromb Hemost 33:695-8. 2007
    ....
  16. ncbi request reprint Current perspectives on primary prophylaxis and patient risk factors for venous thromboembolism in the cancer patient
    Howard A Liebman
    Keck School of Medicine, University of Southern California, Los Angeles 90033, USA
    Cancer Control 12:11-6. 2005
  17. ncbi request reprint Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance
    Casey L O'Connell
    Division of Hematology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
    J Clin Oncol 24:4928-32. 2006
    ..We hypothesized that these patients had signs or symptoms suggestive of PE that may have been overlooked by their health care providers...
  18. doi request reprint Predictive model of venous thromboembolism in endometrial cancer
    Koji Matsuo
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA
    Gynecol Oncol 128:544-51. 2013
    ..To profile characteristics and survival of endometrial cancer patients who develop venous thromboembolism (VTE) and to establish a predictive model of VTE in endometrial cancer...
  19. doi request reprint Managing cancer-related venous thromboembolic disease: low-molecular-weight heparins and beyond
    Casey L O'Connell
    Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
    Expert Rev Hematol 1:175-82. 2008
    ....
  20. ncbi request reprint Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment
    Douglas E Sutherland
    Division of Hematology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    Am J Hematol 72:43-52. 2003
    ..The purpose of this review is to examine our current understanding of thrombosis as a complication of cancer and cancer therapy. The review includes a discussion of the epidemiology, pathophysiology, diagnosis and treatment...
  21. ncbi request reprint Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura
    Sandeep K Rajan
    Division of Hematology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
    Br J Haematol 129:818-24. 2005
    ..001 compared with HCV-TP). HCV infection can be associated with significant thrombocytopenia and appears to be a distinct clinical entity...
  22. ncbi request reprint Rituximab treatment for resistant antiphospholipid syndrome
    Elyse Rubenstein
    Division of Rheumatology and Division of Hematology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, 90033, USA
    J Rheumatol 33:355-7. 2006
    ..Since rituximab infusion, all the patients have had stable platelet counts and no further episodes of bleeding or thromboses...
  23. ncbi request reprint Anticoagulation is an effective treatment for aortic mural thrombi
    Michael E Bowdish
    Division of Vascular Surgery, Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    J Vasc Surg 36:713-9. 2002
    ..Aortic mural thrombi (AMT) in the absence of aortic disease are rare. The appropriate indications and the efficacy of surgical thrombectomy, thrombolysis, and systemic anticoagulation remain controversial...
  24. doi request reprint The immune thrombocytopenia syndrome: a disorder of diverse pathogenesis and clinical presentation
    Douglas B Cines
    Department of Medicine and Pathology, University of Pennsylvania, Philadelphia, PA, USA
    Hematol Oncol Clin North Am 23:1155-61. 2009
    ....
  25. doi request reprint Management of immune-mediated cytopenias in pregnancy
    Caroline I Piatek
    Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California USC Norris Cancer Center, USC University Hospital, 1441 Eastlake Avenue, Norris Topping Tower 3463, MC 9172, Los Angeles, CA 90033 9172, USA
    Autoimmun Rev 14:806-11. 2015
    ..This article summarizes immune cytopenias seen in pregnant patients, and it also discusses management of these cytopenias, and provides practical strategies for the treatment of these challenging conditions. ..
  26. ncbi request reprint Approach to the management of incidental venous thromboembolic events in patients with cancer
    Casey L O'Connell
    From Jane Ann Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California Keck School of Medicine, Los Angeles, California
    J Natl Compr Canc Netw 12:1557-60. 2014
    ....
  27. doi request reprint Thyroid disease in patients with immune thrombocytopenia
    Eric Cheung
    University of Southern California Keck School of Medicine, Jane Anne Nohl Division of Hematology, Norris Comprehensive Cancer Center, Room 3466, 1441 Eastlake Avenue, Los Angeles, CA 90033 0800, USA
    Hematol Oncol Clin North Am 23:1251-60. 2009
    ..These patients may be further screened with a thyroid-stimulating hormone assay to detect subclinical thyroid disease...
  28. doi request reprint Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics
    Howard A Liebman
    Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Hematology Am Soc Hematol Educ Program 2011:384-90. 2011
    ..In this article, we review the current data on the efficacy and safety of thrombopoietin receptor agonists and discuss other therapies as well as diagnostic work up of ITP...
  29. ncbi request reprint Progressive prothrombotic state in women with advancing HIV disease
    Alexandra M Levine
    Department of Medicine, Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, 90033, USA
    J Acquir Immune Defic Syndr 42:572-7. 2006
    ..HIV-infected patients are at increased risk for venous thrombotic events (VTEs). We sought to determine if advancing stages of HIV were associated with coagulation abnormalities that could predispose to VTE...
  30. ncbi request reprint Thrombosis in patients with paroxysmal noctural hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor
    Howard A Liebman
    Division of Hematology, Department of Medicine, University of Southern California Keck School of Medicine, Kenneth Norris Jr Cancer Center, Rm 3466, 1441 Eastlake Ave, Los Angeles, CA 90033, USA
    Thromb Res 111:235-8. 2003
    ..We propose that thrombosis in PNH results from increased tissue factor expression by complement injured CD55- and CD59-deficient monocytes and macrophages...